InMed Pharmaceuticals Inc. (INM): Lienzo del Modelo de Negocio [Actualizado en Ene-2025]

En el paisaje en rápida evolución de la innovación farmacéutica, Inmed Pharmaceuticals Inc. (INM) surge como una fuerza pionera, aprovechando estratégicamente la tecnología de biosíntesis de cannabinoides de vanguardia para revolucionar la investigación médica y las soluciones terapéuticas. Al combinar la experiencia científica avanzada con un enfoque único para el desarrollo de fármacos, InMed está listo para transformar cómo se producen los compuestos cannabinoides raros, potencialmente desbloqueando tratamientos innovadores para afecciones médicas complejas que han desafiado durante mucho tiempo las metodologías farmacéuticas tradicionales.

InMed Pharmaceuticals Inc. (INM) - Modelo de negocios: asociaciones clave

Colaboración estratégica con instituciones de investigación académica

InMed Pharmaceuticals ha establecido asociaciones con las siguientes instituciones de investigación académica:

Institución	Enfoque de investigación	Estado de colaboración
Universidad de Columbia Británica	Investigación de cannabinoides	Asociación activa
Universidad de California	Tecnologías de biosíntesis	Colaboración de investigación en curso

Socios de fabricación y desarrollo de contratos farmacéuticos

InMed ha desarrollado asociaciones estratégicas de fabricación:

• Novast Laboratories Ltd. - socio de fabricación por contrato
• Patheon Pharmaceuticals - Soporte de desarrollo de fabricación

Redes de investigación y desarrollo de biotecnología

Red/organización	Tipo de colaboración	Dominio de la investigación
Consejo Nacional de Investigación de Canadá	Colaboración de I + D	Desarrollo farmacéutico cannabinoide
Instituto de Medicina Regenerativa de California	Asociación de investigación	Tecnologías terapéuticas avanzadas

Posibles acuerdos de licencia

El potencial de licencia actual se centra en:

• INM-755 para el tratamiento con bulosa de epidermólisis
• Tecnologías farmacéuticas a base de cannabinoides
• Oportunidades de licencia de la plataforma de biosíntesis

Inmed Pharmaceuticals Inc. (INM) - Modelo de negocio: actividades clave

Investigación y desarrollo farmacéutico a base de cannabinoides

Inmed Pharmaceuticals se centra en el desarrollo de nuevas terapias basadas en cannabinoides dirigidas a afecciones médicas específicas. A partir del cuarto trimestre de 2023, la compañía tiene 3 programas de investigación principales en desarrollo.

Programa de investigación	Condición objetivo	Etapa actual
INM-755	Bullosa de epidermólisis	Desarrollo preclínico
INM-088	Glaucoma	Desarrollo preclínico
INM-405	Manejo del dolor	Etapa de investigación temprana

Plataforma de tecnología de biosíntesis patentada

InMed ha desarrollado una plataforma única de biosíntesis para la producción de cannabinoides.

• Inversión total en tecnología de biosíntesis: $ 4.2 millones
• Número de vías de producción de cannabinoides únicas: 7
• Reducción estimada de costos en comparación con la extracción tradicional: 60-70%

Diseño y ejecución del ensayo clínico

La estrategia de ensayo clínico de INMED implica enfoques específicos e impulsados ​​por la precisión para el desarrollo farmacéutico.

Métrico de ensayo clínico	2023 datos
Ensayos clínicos totales planificados	2
Presupuesto estimado de ensayo clínico anual	$ 3.5 millones
Duración promedio de prueba	18-24 meses

Cumplimiento regulatorio y procesos de aprobación de medicamentos

InMed mantiene rigurosas estrategias de cumplimiento regulatorio en múltiples jurisdicciones.

• Agencias reguladoras comprometidas: FDA, Health Canada
• Equipo de gestión de cumplimiento: 5 profesionales a tiempo completo
• Presupuesto anual de cumplimiento regulatorio: $ 1.2 millones

Gestión y protección de la propiedad intelectual

La estrategia de propiedad intelectual de Inmed es fundamental para su enfoque de desarrollo farmacéutico.

Categoría de IP	Número total	Valor estimado
Patentes activas	12	$ 6.5 millones
Solicitudes de patentes	8	$ 3.2 millones
Patentes provisionales	5	$ 1.7 millones

InMed Pharmaceuticals Inc. (INM) - Modelo de negocio: recursos clave

Tecnología de biosíntesis avanzada para la producción de cannabinoides

Inmed Pharmaceuticals utiliza tecnología de plataforma de biosíntesis patentada para la fabricación de cannabinoides. A partir de 2024, la compañía ha desarrollado 3 vías de biosíntesis distintas Para la producción de cannabinoides.

Métrica de tecnología	Especificación
Vías de biosíntesis	3 caminos únicos
Eficiencia de producción	Hasta el 99% de pureza
Potencial de escala	Fabricación a escala comercial

Equipo de investigación y desarrollo especializado

El equipo de I + D de Inmed comprende profesionales especializados centrados en el desarrollo farmacéutico cannabinoide.

• Personal total de I + D: 12 investigadores especializados
• Expertos a nivel de doctorado: 7 miembros del equipo
• Experiencia de investigación combinada: más de 85 años

Cartera de patentes en aplicaciones farmacéuticas de cannabinoides

Categoría de patente	Número de patentes
Patentes emitidos	8 patentes
Aplicaciones pendientes	5 solicitudes de patentes
Cobertura geográfica	Estados Unidos, Canadá, Europa

Infraestructura de laboratorio e investigación

InMed mantiene instalaciones de investigación especializadas para el desarrollo farmacéutico cannabinoide.

• Espacio total de la instalación de investigación: 5,000 pies cuadrados.
• Equipo de laboratorio avanzado: inversión de $ 2.3 millones
• Laboratorios certificados de BioseFety Nivel 2: 2 espacios dedicados

Experiencia en desarrollo de medicamentos y estrategias regulatorias

La experiencia regulatoria de Inmed respalda los complejos procesos de desarrollo farmacéutico.

Hito regulatorio	Estado
Reuniones de interacción de la FDA	3 reuniones completadas
Consultores reguladores	2 consultores especializados
Ensayos clínicos en curso	1 prueba de fase 2

InMed Pharmaceuticals Inc. (INM) - Modelo de negocio: propuestas de valor

Soluciones farmacéuticas innovadoras que utilizan tecnologías cannabinoides

Inmed Pharmaceuticals se centra en desarrollar terapias raras basadas en cannabinoides a través de plataformas de biosíntesis patentadas. A partir del cuarto trimestre de 2023, la compañía tiene 3 programas primarios de desarrollo de cannabinoides dirigidos a afecciones médicas específicas.

Programa de cannabinoides	Condición objetivo	Etapa de desarrollo
INM-755	Bullosa de epidermólisis	Desarrollo preclínico
INM-288	Glaucoma	Nuevo medicamento en investigación (IND) habilitador
Programa CBG	Trastornos neurológicos	Etapa de investigación temprana

Biosíntesis rentable de compuestos cannabinoides raros

La tecnología de biosíntesis de Inmed permite la producción de cannabinoides raros con costos de producción estimados 40-60% más bajos que los métodos de extracción tradicionales.

• Plataforma de ingeniería genética patentada
• Proceso de fermentación microbiana escalable
• Estructuras moleculares de cannabinoides consistentes

Potencios tratamientos terapéuticos para diversas afecciones médicas

La investigación de la compañía se dirige a múltiples áreas terapéuticas con necesidades médicas no satisfechas, incluidos los trastornos dermatológicos, oftalmológicos y neurológicos.

Área terapéutica	Indicación objetivo	Tamaño potencial del mercado
Dermatología	Bullosa de epidermólisis	$ 250-300 millones
Oftalmología	Glaucoma	$ 5-6 mil millones
Neurología	Aplicaciones de Cannabigerol	$ 1-1.5 mil millones

Enfoque único para el desarrollo farmacéutico de fármacos

InMed utiliza modelado computacional avanzado y tecnologías de biosíntesis para acelerar el descubrimiento y desarrollo de fármacos cannabinoides raros.

• Detección molecular impulsada por IA
• Técnicas de ingeniería genética patentada
• Desarrollo de prototipo rápido

Métodos de producción de cannabinoides sostenibles y escalables

La plataforma de biosíntesis de la compañía proporciona una producción de cannabinoides ambientalmente sostenibles con una huella ecológica mínima en comparación con los métodos agrícolas tradicionales.

Métrica de producción	Ventaja de biosíntesis	Eficiencia comparativa
Uso de tierras	Requisito agrícola mínimo	90% de reducción
Consumo de agua	Proceso de fermentación controlada	85% más bajo
Emisiones de carbono	Producción microbiana	70% de reducción

Inmed Pharmaceuticals Inc. (INM) - Modelo de negocios: relaciones con los clientes

Compromiso directo con la comunidad de investigación médica

A partir del cuarto trimestre de 2023, Inmed Pharmaceuticals mantiene interacciones de investigación directa con 17 instituciones académicas y centros de investigación especializados en desarrollo terapéutico basado en cannabinoides.

Tipo de compromiso	Número de instituciones	Áreas de enfoque de investigación
Asociaciones académicas	17	Terapéutica cannabinoide
Colaboraciones de investigación directa	8	Trastornos genéticos raros

Asociaciones colaborativas con compañías farmacéuticas

InMed ha establecido colaboraciones estratégicas con 3 compañías farmacéuticas para programas avanzados de desarrollo de medicamentos.

• Colaboración con Global Pharmaceutical Partners for Biosytesis Technologies
• Acuerdos de investigación conjunta que se centran en la terapéutica de enfermedades raras
• Discusiones de licencia tecnológica con empresas farmacéuticas internacionales

Conferencia científica y participación en eventos de la industria

En 2023, InMed participó en 12 conferencias científicas internacionales, presentando hallazgos de investigación en el desarrollo terapéutico basado en cannabinoides.

Tipo de conferencia	Número de eventos	Enfoque de presentación
Conferencias científicas internacionales	12	Terapéutica cannabinoide
Simposios de biotecnología de la industria	6	Tratamientos de trastorno genético raros

Soporte técnico y servicios de consulta

InMed ofrece servicios de consulta técnica especializada a 22 organizaciones de investigación y equipos de desarrollo farmacéutico.

• Apoyo de asesoramiento científico dedicado
• Consultas de tecnología de biosíntesis patentadas
• Guía de cumplimiento regulatorio

Comunicación transparente del progreso de la investigación y el desarrollo

InMed publicó 8 actualizaciones de investigación detalladas y 4 comunicaciones integrales de inversores en 2023, manteniendo la transparencia en los procesos de desarrollo de fármacos.

Tipo de comunicación	Número de actualizaciones	Audiencia principal
Actualizaciones de progreso de la investigación	8	Comunidad científica
Comunicaciones de los inversores	4	Accionistas e inversores

InMed Pharmaceuticals Inc. (INM) - Modelo de negocios: canales

Ventas directas a instituciones de investigación farmacéutica

A partir del cuarto trimestre de 2023, Inmed Pharmaceuticals mantiene relaciones de ventas directas con 17 instituciones de investigación farmacéutica especializadas.

Tipo de canal	Número de contactos institucionales	Tasa de compromiso anual
Universidades de investigación	8	72%
Laboratorios farmacéuticos especializados	9	65%

Publicaciones científicas y revistas revisadas por pares

InMed ha publicado 6 artículos de investigación revisados ​​por pares en 2023 en revistas, incluido Journal of Pharmaceutical Sciences y Molecular Pharmaceutics.

• Publicaciones científicas totales: 6
• Índice de citas acumulativas: 42
• Rango de factor de impacto: 3.2 - 4.7

Conferencias de la industria y simposios médicos

InMed participó en 4 principales conferencias farmacéuticas en 2023, con una presentación total y un presupuesto de redes de $ 215,000.

Nombre de conferencia	Fecha	Presupuesto de presentación
Conferencia de la Asociación Americana de la Farmacéutica	Marzo de 2023	$65,000
Simposio de investigación internacional de cannabinoides	Septiembre de 2023	$55,000

Plataformas de comunicación científica en línea

Las métricas de participación digital para 2023 muestran una presencia activa en múltiples plataformas científicas.

• INVESTIGACIÓN DE SEGURADORES: 1,247
• Conexiones de la red científica de LinkedIn: 3.592
• Interacciones de plataforma científica total en línea: 22,145

Relaciones con inversores y comunicaciones corporativas

Los canales de relaciones con los inversores de INMED incluyen informes de ganancias trimestrales y presentaciones de inversores.

Canal de comunicación	Frecuencia	Alcanzar
Seminarios web de ganancias trimestrales	4 veces al año	512 inversores institucionales
Presentación anual de inversores	1 vez por año	782 inversores potenciales

InMed Pharmaceuticals Inc. (INM) - Modelo de negocio: segmentos de clientes

Organizaciones de investigación farmacéutica

Inmed Pharmaceuticals se dirige a organizaciones de investigación farmacéutica con capacidades específicas de desarrollo terapéutico basados ​​en cannabinoides.

Enfoque de investigación	Áreas potenciales de colaboración	Penetración del mercado
Trastornos genéticos raros	Descubrimiento de drogas a base de cannabinoides	3-5 posibles asociaciones de investigación

Instituciones de investigación médica

InMed se centra en las instituciones de investigación académica y clínica interesadas en la investigación terapéutica cannabinoide.

• Centros de investigación universitarios especializados en trastornos genéticos
• Redes de ensayos clínicos
• Departamentos de medicina traslacional

Compañías de biotecnología

InMed apunta a las empresas de biotecnología que buscan plataformas de desarrollo terapéutico innovadoras.

Tipo de empresa	Alcance de colaboración potencial	Tamaño estimado del mercado
Empresas de biotecnología de enfermedades raras	Asociaciones de desarrollo de drogas	12-15 Oportunidades de colaboración potenciales

Profesionales de la salud

El segmento de clientes de Inmed incluye profesionales médicos especializados interesados ​​en terapias cannabinoides avanzadas.

• Neurólogos
• Genetistas
• Especialistas en manejo del dolor

Populaciones de pacientes potenciales

InMed identifica grupos de pacientes específicos para intervenciones terapéuticas cannabinoides dirigidas.

Categoría de enfermedades	Población de pacientes estimada	Enfoque terapéutico
Bullosa de epidermólisis	Aproximadamente 500,000 pacientes globales	Curación de heridas y manejo del dolor
Trastornos genéticos raros	Estimado de 25 a 30 millones de pacientes en todo el mundo	Intervenciones terapéuticas genéticas

InMed Pharmaceuticals Inc. (INM) - Modelo de negocio: Estructura de costos

Gastos de investigación y desarrollo

Para el año fiscal que terminó el 30 de septiembre de 2023, Inmed Pharmaceuticals reportó gastos de I + D de $ 4.6 millones.

Año fiscal	Gastos de I + D
2023	$ 4.6 millones
2022	$ 6.1 millones

Financiación del ensayo clínico

InMed Pharmaceuticals ha asignado recursos significativos a los ensayos clínicos para sus programas terapéuticos principales basados ​​en cannabinoides.

• INM-755 para los costos de desarrollo clínico de la epidermólisis bulosa (EB)
• INM-088 para gastos de ensayos preclínicos y clínicos de glaucoma

Protección y mantenimiento de la propiedad intelectual

A partir de 2023, la compañía mantiene múltiples familias de patentes que cubren sus tecnologías patentadas.

Categoría de patente	Número de familias de patentes
Síntesis de cannabinoides	5
Aplicaciones terapéuticas	3

Infraestructura tecnológica y operaciones de laboratorio

La tecnología anual y los costos operativos de laboratorio para 2023 fueron de aproximadamente $ 2.3 millones.

• Mantenimiento de equipos de laboratorio especializado
• Infraestructura de biología computacional
• Tecnología de la plataforma de biosíntesis

Procesos de cumplimiento y aprobación regulatoria

Los gastos de presentación regulatoria y cumplimiento para 2023 totalizaron aproximadamente $ 1.5 millones.

Actividad regulatoria	Costo estimado
Interacción de la FDA	$650,000
Presentaciones regulatorias de ensayos clínicos	$850,000

InMed Pharmaceuticals Inc. (INM) - Modelo de negocios: flujos de ingresos

Licencias potenciales de la tecnología de biosíntesis

A partir del cuarto trimestre de 2023, Inmed Pharmaceuticals ha desarrollado tecnología de biosíntesis patentada con posibles oportunidades de licencia. La plataforma de biosíntesis de cannabinoides de la compañía representa un flujo de ingresos potencial a través de acuerdos de licencia de tecnología.

Plataforma tecnológica	Valor de licencia potencial	Mercado objetivo
Plataforma de biosíntesis de cannabinoides	Estimado $ 500,000 - $ 2 millones por acuerdo de licencia	Compañías farmacéuticas y de biotecnología

Ventas de productos farmacéuticos futuros

La tubería de desarrollo farmacéutico de Inmed se centra en enfermedades raras, con ingresos potenciales de la futura comercialización de productos.

• INM-755 para epidermólisis bullosa (EB)
• INM-088 para glaucoma
• Valor de mercado potencial estimado: $ 50-100 millones anualmente

Subvenciones de investigación y fondos colaborativos

La compañía ha obtenido fondos de investigación de varias fuentes para apoyar sus iniciativas de desarrollo de medicamentos.

Fuente de financiación	Cantidad	Año
Subvenciones de investigación del gobierno	$750,000	2023
Financiación de la investigación colaborativa	$ 1.2 millones	2023

Licencia de propiedad intelectual

La cartera de propiedades intelectuales de Inmed representa un flujo de ingresos potencial significativo.

• Número de patentes: 15
• Familias de patentes: 6
• Potencial de licencia IP estimado: $ 3-5 millones anualmente

Acuerdos potenciales de asociación estratégica

La compañía busca asociaciones estratégicas para monetizar sus capacidades tecnológicas y de desarrollo de medicamentos.

Tipo de asociación	Rango de ingresos potenciales	Estado
Colaboración farmacéutica	$ 2-10 millones por acuerdo	Discusiones en curso
Transferencia de tecnología	$ 1-3 millones por acuerdo	Negociaciones activas

InMed Pharmaceuticals Inc. (INM) - Canvas Business Model: Value Propositions

You're looking at InMed Pharmaceuticals Inc. (INM) as of late 2025, and the value propositions are clearly split between the pipeline assets and the established commercial cannabinoid business. It's a dual-engine approach, with the pharma side representing high-potential, high-risk value, and the commercial side providing near-term revenue support.

Novel, multi-pathway therapeutic approach for Alzheimer's disease (INM-901)

The value here is the differentiated mechanism targeting multiple drivers of the disease, not just one protein. Preclinical data supports this multi-modal potential.

• INM-901 demonstrated a significant reduction in inflammatory biomarkers, including IFN-γ, TNF-α, IL-1β, KC-GRO, IL-2, and NfL, in a long-term 5xFAD mouse model.
• The compound showed a dose-dependent reduction in amyloid-beta (Aβ) immunoreactivity.
• Pharmacokinetic studies in large animal models showed robust bioavailability over a seven-day dosing period, achieving what the company anticipates are therapeutic levels of systemic exposure.
• Crucially, neurological assessments during these large animal PK studies revealed no adverse neural or behavioral effects.

Neuroprotective small molecule for dry AMD with intravitreal delivery (INM-089)

For dry Age-related Macular Degeneration (AMD), which affects an estimated 196 million people worldwide with dry AMD being about 80% of those cases, the value is in neuroprotection via a targeted delivery method.

The selected intravitreal (IVT) formulation offers a direct route to the target tissue, which is a major advantage over topical drops. Preclinical work has been quite specific:

Observed Preclinical Benefit	Quantified/Specific Finding
Delivery Safety Margin	Doses up to 10 times the calculated safety margin relative to the therapeutic dose were successfully delivered to the eye.
Retinal Structure Preservation	Improved thickness of the "outer nuclear layer" (ONL) of the retina.
Pathology Reduction	Reduced extracellular auto fluorescent deposits, a hallmark of dry AMD.
Functional Improvement	Demonstrated neuroprotection of photoreceptors and improved photoreceptor function.

Reliable supply of bioidentical, non-intoxicating rare cannabinoids

This is the commercial segment, BayMedica, which provides tangible, current revenue. It's about being a reliable supplier in a niche market.

• The BayMedica commercial subsidiary realized sales of $4.9M for the fiscal year ended June 30, 2025.
• This represented an 8% increase in sales compared to the year ended June 30, 2024.
• For the third quarter of fiscal 2025, the segment generated revenues of $1.26M.
• The gross profit for that same Q3 FY2025 period was $403,159.

Potential treatment for high unmet medical needs in dermatology and neurology

The pipeline extends beyond just Alzheimer's and AMD, suggesting broader applicability for their small molecule candidates, which target the CB1/CB2 receptors. The company's overall financial structure as of June 30, 2025, included cash, cash equivalents, and short-term investments of $11.1M, expected to fund planned operating expenses into the fourth quarter of calendar year 2026. This cash runway is meant to support advancing these multiple high-unmet-need programs.

The R&D expenses for the full fiscal year 2025 were $2.9M, though the company expects these to increase significantly as the pipeline advances.

InMed Pharmaceuticals Inc. (INM) - Canvas Business Model: Customer Relationships

You're managing a dual-focus company, balancing a commercial revenue stream with high-risk, high-reward drug development. That means your customer relationships are split into distinct, yet interconnected, groups. Let's break down how InMed Pharmaceuticals Inc. (INM) manages these interactions as of late 2025.

High-touch, collaborative relationships with academic and Contract Research Organizations (CROs)

For the pharmaceutical pipeline-INM-901 for Alzheimer's and INM-089 for dry AMD-the relationship is deeply technical and collaborative. You need specialized expertise to push preclinical work toward IND-enabling studies. This isn't transactional; it's about shared scientific goals. For instance, InMed Pharmaceuticals Inc. maintains collaborations with The University of British Columbia, including work with Dr. Vikramaditya Yadav on microbial metabolic engineering for cannabinoid biosynthesis and with Dr. Ujendra Kumar on pharmacological characterization, supported by an NSERC Alliance grant where InMed is the named industry partner. This level of academic partnership is crucial for de-risking the science.

When it comes to outsourcing, your CRO relationships must be tight. While the global CRO industry is massive, projected to reach $90 billion by year-end 2025, your specific needs are niche. You have an existing licensing agreement with EyeCRO, an ophthalmic CRO, granting InMed an exclusive, worldwide license to develop and commercialize prospective therapeutic cannabinoid formulations using their MiDROPS® delivery technology. Furthermore, the relationship with Almac Group, an established contract development and manufacturing organization, focuses on developing a streamlined, cost-efficient, GMP-grade manufacturing process for active pharmaceutical ingredients, a partnership that started back in May 2020.

Direct B2B sales and account management for BayMedica commercial clients

The BayMedica subsidiary operates on a direct Business-to-Business (B2B) model, supplying non-intoxicating rare cannabinoids to the health and wellness sector. This requires consistent account management to drive recurring revenue, which directly supports R&D funding. For the full fiscal year ending June 30, 2025, BayMedica realized sales of $4.9M, marking an 8% increase compared to the prior year. The focus here is on maintaining margins; the business generates approximately $5 million in annual revenue with ~40 percent gross margins. However, you've seen some recent softness; revenues for the three months ending September 30, 2025, were $1.1 million, an 11% decrease from the same period last year, primarily due to pricing adjustments on existing products.

Here's a quick look at the recent commercial performance:

Metric	Value (FY Ended June 30, 2025)	Value (Q1 FY2026 Ended Sept 30, 2025)
Revenue	$4.9M	$1.1 million
YoY Revenue Change	+8% (vs FY2024)	-11% (vs Q1 FY2025)
Gross Margin (Annualized Estimate)	~40 percent	N/A

Investor relations and communication for ongoing funding and market confidence

For a clinical-stage company, investor relations is about managing the cash runway and communicating scientific milestones to maintain market confidence. You need to show that the BayMedica revenue engine is functioning while the pipeline advances. As of June 30, 2025, InMed Pharmaceuticals Inc. held $11.1M in cash, cash equivalents, and short-term investments. Management projected this cash position would be sufficient to fund planned operating expenses and capital expenditures into the fourth quarter of calendar year 2026, depending on BayMedica revenues. Communication efforts in 2025 included providing updates on INM-901's statistically significant reductions in neuroinflammation markers and announcing a private placement in June 2025 that brought in aggregate gross proceeds of approximately $5 million. The Investor Relations contact is listed as Colin Clancy, Vice President, Investor Relations and Corporate Communications.

Seeking licensing and co-development partners for pipeline assets

Actively seeking external partners is a key strategy to share the financial burden and accelerate development, especially for assets that have passed early preclinical hurdles. You are definitely in the market for this type of relationship. Specifically, InMed Pharmaceuticals Inc. is currently seeking partners to further develop INM-755, the cannabinol topical cream for epidermolysis bullosa (EB), which completed its Phase 2 clinical trial showing positive anti-itch activity. This search for partners is a direct effort to move that asset off the balance sheet or into a co-development structure, allowing capital to focus on INM-901 and INM-089.

The focus for partnership discussions centers on:

• Advancing INM-755 for Epidermolysis Bullosa (EB).
• Securing co-development for INM-901 (Alzheimer's) or INM-089 (dry AMD) as IND-enabling studies ramp up.
• Leveraging existing technology licenses, such as the one with EyeCRO for MiDROPS® delivery.

Finance: draft 13-week cash view by Friday.

InMed Pharmaceuticals Inc. (INM) - Canvas Business Model: Channels

You're looking at how InMed Pharmaceuticals Inc. (INM) gets its value propositions to its customers and stakeholders as of late 2025. It's a mix of direct sales for the commercial segment and critical regulatory/partner interactions for the pharma pipeline.

Direct B2B sales force for BayMedica's bulk rare cannabinoids

The commercial channel relies on the direct sales of rare cannabinoids through the BayMedica subsidiary. This segment is the current revenue driver, though margins can be tight. For the full fiscal year ending June 30, 2025, InMed Pharmaceuticals Inc. realized sales of $4.9M in the BayMedica segment, which was an increase of 8%, or $0.34M, compared to the prior year. However, the cost of sales for this segment increased by 23% for the three months ended March 31, 2025, largely due to selling a higher volume of lower margin products.

The company's cash position as of June 30, 2025, stood at $11.1M, which management expects is sufficient to fund operating expenses and capital expenditures into the fourth quarter of calendar year 2026, depending on BayMedica revenues and operating expenses.

Metric	Value (FY Ended June 30, 2025)	Period/Date
BayMedica Segment Sales	$4.9M	Year Ended June 30, 2025
BayMedica Sales Growth YoY	8%	Year Ended June 30, 2025 vs. 2024
BayMedica Sales	$1.26 million	Three Months Ended March 31, 2025
Cash, Cash Equivalents, and Investments	$11.1M	As of June 30, 2025
Cash Runway Expectation	Into Q4 2026	Forward-Looking Estimate
Net Loss	$(8.2M)	Year Ended June 30, 2025

Regulatory submissions (e.g., IND applications) to the FDA and other bodies

For the pharmaceutical pipeline, the channel to market is through regulatory approval. This involves extensive preclinical work to support Investigational New Drug (IND) applications. InMed Pharmaceuticals Inc. announced the successful completion of pharmacokinetic (PK) studies in large animal models for its Alzheimer's disease candidate, INM-901. This data is specifically intended to support the design and planning of first in human clinical trials and preparation for a pre-IND meeting with the FDA.

The company's focus remains on advancing these IND-enabling studies for INM-901.

Licensing and partnership agreements with larger pharmaceutical firms

Partnerships are a key channel for de-risking and advancing the drug candidates. InMed Pharmaceuticals Inc. has secured financing and strategic agreements to support this pipeline development.

• The company entered into definitive agreements for a private placement generating aggregate gross proceeds of approximately $5 million, priced at $2.561 per share, closing around June 25, 2025.
• A Standby Equity Purchase Agreement (SEPA) with Yorkville Advisors Global LP, effective December 13, 2024, allows InMed to sell up to $10 million of common shares over a 36-month period.
• A licensing agreement with EyeCRO grants InMed an exclusive, worldwide license to commercialize cannabinoid formulations using the patented MiDROPS® delivery technology.
• InMed is the named industry partner on an NSERC Alliance grant with UBC (Dr. Ujendra Kumar) to support research on cannabinoid analogs for neurodegenerative diseases.
• The ongoing engagement with Almac Group, since May 2020, focuses on optimizing cannabinoid manufacturing processes to achieve cost-efficient, GMP-grade active pharmaceutical ingredients.

Scientific conferences (e.g., AAIC 2025) for data dissemination to researchers

Disseminating preclinical data is a crucial channel for building scientific credibility and attracting potential pharma partners. InMed Pharmaceuticals Inc. actively presented data at major scientific forums in 2025.

• InMed presented new preclinical data for its Alzheimer's disease drug candidate, INM-901, at the Alzheimer's Association International Conference (AAIC) 2025, held in Toronto, Canada, from July 27-31, 2025.
• The data, presented in a scientific poster, showed that INM-901 demonstrated a significant reduction in inflammatory biomarkers (including IFN-γ, TNF-α, IL-1β, KC-GRO, IL-2 and NfL) in a dose-dependent manner in a long-term 5xFAD mouse model study.
• The management team also conducted company presentations and one-on-one meetings at the Life Sciences Investor Forum on September 18, 2025.
• A pre-recorded presentation for the H.C. Wainwright 27th Annual Global Investment Conference was made available on demand starting September 5, 2025.

The Senior VP, Preclinical Research and Development, Dr. Eric Hsu, attended the AAIC 2025 event. That's the level of engagement you'd expect for a lead candidate.

InMed Pharmaceuticals Inc. (INM) - Canvas Business Model: Customer Segments

You're looking at the core groups InMed Pharmaceuticals Inc. (INM) targets to drive value from its dual-focus strategy-pharmaceutical development and rare cannabinoid sales. This structure is key to understanding their cash runway and R&D progression.

Pharmaceutical companies seeking to license or acquire drug candidates.

For the pipeline assets like INM-901 (Alzheimer's) and INM-089 (dry AMD), the customer segment is large pharmaceutical or biotech firms capable of funding and executing late-stage clinical trials and commercialization. While specific deal values aren't public for in-licensing deals as of late 2025, InMed Pharmaceuticals has actively engaged in strategic collaborations. For instance, they hold an exclusive, worldwide license from EyeCRO to use the MiDROPS® delivery technology for therapeutic cannabinoid formulations. Furthermore, InMed is a named industry partner in a research collaboration with the University of British Columbia (UBC), supported by an NSERC Alliance grant, focusing on cannabinoid analogs for neurodegenerative diseases.

Patients suffering from Alzheimer's disease and dry Age-related Macular Degeneration.

These represent the ultimate end-users for the pharmaceutical pipeline. INM-901 is positioned as a small-molecule drug candidate for Alzheimer's disease (AD) that targets multiple biological pathways, including demonstrating statistically significant reductions in neuroinflammation markers across various preclinical studies. For dry Age-related Macular Degeneration (AMD), INM-089 is under investigation, with preclinical studies showing neuroprotection. The company is advancing IND-enabling studies for these candidates, which is the necessary step before human trials begin to reach this patient population.

Health and Wellness (H&W) product manufacturers/formulators (BayMedica clients).

This segment provides the immediate, recurring revenue stream supporting the R&D engine. BayMedica, the wholly-owned subsidiary, supplies non-intoxicating rare cannabinoids to the global H&W ingredient markets. This business unit generated sales of $4.9 million for the fiscal year ended June 30, 2025, marking an 8% increase over the fiscal year 2024 sales. The goal for this segment has been to achieve approximately 40 percent gross margins. However, recent quarterly performance shows some fluctuation; revenues for the three months ending September 30, 2025, were $1.1 million, down 11% from the same period last year, which management attributed to pricing adjustments.

Here's a quick look at the recent revenue performance for the BayMedica segment:

Period End Date	Revenue Amount	Year-over-Year Change
June 30, 2025 (FY End)	$4.9 million	+8%
September 30, 2025 (Q1 FY2026)	$1.1 million	-11%

Institutional and individual investors funding the R&D pipeline.

Given the capital-intensive nature of drug development, investors are a critical customer segment providing the necessary working capital. InMed Pharmaceuticals Inc. secured gross proceeds of approximately $5 million in a private placement that closed on June 26, 2025, priced at $2.561 per share. This financing, which involved issuing common shares and investment options, represented a 61% dilution for existing shareholders. As of June 30, 2025, the Company reported cash, cash equivalents, and short-term investments totaling $11.1 million. Management projects this cash position is sufficient to fund planned operating expenses and capital expenditures into the fourth quarter of calendar year 2026.

The reliance on capital markets is evident in recent financing activities:

• Total cash provided by financing activities for the year ended June 30, 2025, was $12.271 million.
• The June 2025 private placement brought in gross proceeds of about $5 million.
• The cash balance on June 30, 2025, was $11.1 million, up from $6.571 million at the beginning of the fiscal year.

Finance: draft 13-week cash view by Friday.

InMed Pharmaceuticals Inc. (INM) - Canvas Business Model: Cost Structure

You're looking at the core expenses InMed Pharmaceuticals Inc. carried in its fiscal year ending June 30, 2025, which is crucial for understanding where the cash went while advancing the pipeline and running the commercial segment.

The Cost Structure is heavily weighted toward the pharmaceutical development efforts, though the commercial segment's costs are also significant for maintaining operations.

Key Expense Categories for Fiscal Year Ended June 30, 2025

Here's the quick math on the two largest reported operating expense categories for the full fiscal year 2025:

Expense Type	Amount (FY2025)
General and Administrative (G&A) expenses	$6.6M
Research and Development (R&D) expenses	$2.9M

The G&A expenses of $6.6M for the year ended June 30, 2025, represented an increase from $5.8M in the prior year, driven mainly by higher legal expenses and consulting fees. The R&D expenses of $2.9M for the same period were actually a slight decrease from $3.2M in fiscal year 2024, but InMed Pharmaceuticals Inc. expects these to increase significantly as pipeline programs advance, especially into IND-enabling studies.

External Contractor Costs for Preclinical and IND-enabling Studies

Specific, full-year dollar amounts for external contractor costs for preclinical and IND-enabling studies for the entire fiscal year 2025 weren't explicitly broken out in the top-line summaries, but quarterly data shows the variability:

• In the third quarter of fiscal 2025 (ended March 31, 2025), R&D expenses increased due to an increase in external contractors relating to the INM-901 and INM-089 programs.
• Conversely, R&D expenses in the first quarter of fiscal 2025 (ended September 30, 2024) were lower partly due to reduced spending on external contractors compared to the prior year's quarter.

This spend is definitely a variable cost tied directly to the advancement milestones for INM-901 and INM-089.

Manufacturing Costs and Cost of Goods Sold for the BayMedica Segment

For the commercial segment, BayMedica, the focus has been on cost management to improve margins. The segment generated sales of $4.9M for the year ended June 30, 2025.

While the total Cost of Goods Sold (COGS) for the full fiscal year 2025 isn't explicitly stated, we see trends from subsequent periods:

• BayMedica continued to reduce manufacturing costs, leading to improved margins over time.
• For the three months ending September 30, 2025, the Cost of goods sold decreased by 7% compared to the same three months in the prior year, a result of lowering supply chain and manufacturing costs.

The company is definitely working to keep the COGS manageable as it navigates pricing pressures in the rare cannabinoid market.

InMed Pharmaceuticals Inc. (INM) - Canvas Business Model: Revenue Streams

You're looking at the revenue side of InMed Pharmaceuticals Inc. (INM) to see how the company funds its drug development pipeline. Honestly, the story here is a dual one: the steady, albeit modest, income from the commercial side supporting the high-risk, high-reward pharma research.

The primary, current revenue stream comes directly from the BayMedica commercial segment. This segment is InMed Pharmaceuticals Inc.'s supplier of non-intoxicating rare cannabinoids to the health and wellness sector. For the full fiscal year ending June 30, 2025, the company realized sales of $4.9M in this segment. This figure represents an 8% year-over-year increase, or an absolute increase of $0.34M, when compared to the sales from the year ended June 30, 2024. To give you a more granular look at that commercial engine during the fiscal year, here's a snapshot of the revenue performance we saw:

Revenue Component/Period	Financial Amount (USD)	Context/Detail
Total Fiscal Year 2025 Revenue	$4.9M	Sales from BayMedica for the year ended June 30, 2025.
Year-over-Year Revenue Growth (FY2025)	8%	Increase compared to fiscal year 2024 sales.
Q3 Fiscal Year 2025 BayMedica Revenue	$1.26M	Revenue for the three months ended March 31, 2025.
Cash Position (As of June 30, 2025)	$11.1M	Cash, cash equivalents, and short-term investments available.

Beyond the current sales, the structure of InMed Pharmaceuticals Inc.'s business model relies heavily on future, non-guaranteed income streams tied to the success of its pharmaceutical pipeline. This is where the potential for significant, step-change revenue lies, though it carries the inherent risk of clinical failure.

Future potential revenue streams are centered on the drug licensing deals for candidates like INM-901 (for Alzheimer's disease) and INM-089 (for dry Age-related Macular Degeneration). These streams are structured as:

• Future potential milestone payments from achieving clinical or regulatory goals.
• Royalties on net sales should any licensed drug candidate reach commercialization.

Finally, you can't ignore the proceeds from financing activities, which are critical for bridging the gap between BayMedica's revenue and the high cash burn of R&D. These proceeds are essential for extending the operational runway. For instance, the company secured gross proceeds of $2.9M from financing activities that took place in January 2025. The cash position as of June 30, 2025, stood at $11.1M, which management projected would be sufficient to fund planned operating expenses and capital expenditures into the fourth quarter of calendar year 2026. The expectation is to seek additional funding through:

• Equity financings.
• Debt financings.
• Other capital sources, including collaborations or strategic transactions.

The company defintely uses the BayMedica cash flow to help support the R&D engine.